EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis

Miguel Regueiro iD, Britta Siegmund iD, Sara Horst, Ryan Moslin, Lorna Charles, AnnKatrin Petersen, Daniel Tatosian, Hsiuanlin Wu, Garrett Lawlor, Monika Fischer, Geert D'Haens, Jean-Frederic Colombel

Inflammatory Bowel Diseases · 10.04.2025 · 31 (4) · 1010-1017

DOI: 10.1093/ibd/izae136 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 17.07.2024. Verfasst von Miguel Regueiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Antidepressive Agents, Colitis, Ulcerative, Indans, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ozanimod, approved for the treatment of moderately to severely active ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), is a weak in vitro monoamine oxidase B (MAO-B) inhibitor. MAO-B inhibitors can cause serotonin accumulation with concomitant use of selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs). We evaluated the incidence of treatment-emergent adverse events (TEAEs) potentially associated with serotonin accumulation during ozanimod and concomitant SSRI/SNRI use in this post hoc analysis of pooled UC studies and the open-label extension RMS DAYBREAK.

Methods

Data for ozanimod 0.92 mg from pooled UC studies (n = 1158; cutoff: January 10, 2022) and RMS DAYBREAK (n = 2257; cutoff: February 1, 2022) were analyzed. Concomitant SSRI/SNRI use was allowed in the UC (n = 67) and RMS (n = 274) studies. A narrow Medical Dictionary for Regulatory Activities search (“serotonin syndrome,” “neuroleptic malignant syndrome,” and “malignant hyperthermia”) and a broad search including terms potentially associated with serotonin accumulation were conducted. The percentages of patients with TEAEs in both searches were analyzed by concomitant SSRI/SNRI use when the TEAE occurred.

Results

No patients had TEAEs matching the narrow search criteria. No differences were observed in the percentages of patients with ≥1 TEAE matching the broad search regardless of SSRI/SNRI use in UC (with: 25.4% [n = 17 of 67]; without: 15.0% [n = 164 of 1091]) and RMS (with: 12.4% [n = 34 of 274]; without: 15.6% [n = 310 of 1982]) studies.

Conclusions

No evidence of increased TEAEs potentially associated with serotonin accumulation was observed with concurrent use of ozanimod and SSRIs/SNRIs. Clinical trial registration NCT01647516, NCT02531126, NCT02435992, NCT02576717

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsColitis, UlcerativeIndansMultiple Sclerosis, Relapsing-RemittingOxadiazolesSelective Serotonin Reuptake InhibitorsSphingosine 1 Phosphate Receptor ModulatorsAdultFemaleHumansMaleMiddle AgedDrug Therapy, Combination

Stichwörter der Autor:innen

ozanimodsafetyserotonergic antidepressantsserotonin accumulationulcerative colitis

Substanzen

Antidepressive AgentsIndansOxadiazolesozanimodSelective Serotonin Reuptake InhibitorsSphingosine 1 Phosphate Receptor Modulators

Autor:innen und Institutionen

  • Cleveland Clinic, Cleveland, OH, USA.
  • Department of Gastroenterology, Infectious Diseases, and Rheumatology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Vanderbilt University Medical Center, Nashville, TN, USA.
  • Bristol Myers Squibb, Princeton, NJ, USA.
  • Indiana University School of Medicine, Indianapolis, IN, USA.
  • Academic Medical Center Amsterdam, Amsterdam, Netherlands.

ORCID-Profile: Miguel Regueiro, Britta Siegmund

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Regueiro, M., Siegmund, B., Horst, S., Moslin, R., Charles, L., Petersen, A., Tatosian, D., Wu, H., Lawlor, G., Fischer, M., D'Haens, G., & Colombel, J. F. (2025). Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. Inflammatory Bowel Diseases, 31(4), 1010-1017. https://doi.org/10.1093/ibd/izae136

Vancouver

Regueiro M, Siegmund B, Horst S, Moslin R, Charles L, Petersen A, et al. Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. Inflammatory Bowel Diseases. 2025;31(4):1010-1017. doi:10.1093/ibd/izae136

BibTeX
@article{Regueiro2025,
  author = {Regueiro, Miguel and Siegmund, Britta and Horst, Sara and Moslin, Ryan and Charles, Lorna and Petersen, AnnKatrin and Tatosian, Daniel and Wu, Hsiuanlin and Lawlor, Garrett and Fischer, Monika and D'Haens, Geert and Colombel, Jean-Frederic},
  title = {Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {4},
  pages = {1010--1017},
  doi = {10.1093/ibd/izae136}
}
Kostenlos starten →